Australia's Lumos Diagnostics rises after collaboration with AcuityMD

Lumos Diagnostics Holdings

20/11/2025 04:36

** Australia's Lumos Diagnostics LDX.AX rises as much as 14.7% to A$0.195, its biggest intraday rise since November 11

** The diagnostic test tech firm enters into a strategic collaboration with AcuityMD to support the U.S. commercialisation of its FebriDx test

** Co says FebriDx to be commercialised in U.S. through increased visibility into reimbursement performance through its AI-enabled platform

** YTD, LDX stock up 442.9%

 (Reporting by Keshav Singh Chundawat in Bengaluru)

 ((Keshav.singhchundawat@thomsonreuters.com))